McQuade Center, Sentinel Oncology Working on New Therapy
The McQuade Center for Strategic Research and Development (MSRD) will collaborate with Sentinel Oncology for the clinical development of a potential breakthrough treatment for fragile XÂ syndrome (FXS). Under agreement terms, the MSRD, which funds innovative early stage research and development programs, will work with the…